Shares of Knight Therapeutics Inc. (TSE:GUD – Get Free Report) shot up 0.2% during trading on Thursday . The stock traded as high as C$6.09 and last traded at C$6.05. 20,473 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 60,403 shares. The stock had previously closed at C$6.04.
Knight Therapeutics Trading Up 0.2%
The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The firm has a market cap of C$600.70 million, a P/E ratio of -151.25, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.01. The firm’s 50-day simple moving average is C$5.94 and its 200 day simple moving average is C$6.06.
Knight Therapeutics (TSE:GUD – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported C($0.04) earnings per share (EPS) for the quarter. The company had revenue of C$122.63 million for the quarter. Knight Therapeutics had a negative return on equity of 4.04% and a negative net margin of 8.81%. As a group, analysts expect that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.
About Knight Therapeutics
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets.
See Also
- Five stocks we like better than Knight Therapeutics
- Comparing and Trading High PE Ratio Stocks
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- Roth IRA Calculator: Calculate Your Potential Returns
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
